Tsfg LLC Sells 1,499 Shares of Pfizer Inc. (NYSE:PFE)

Tsfg LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 23.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 4,912 shares of the biopharmaceutical company’s stock after selling 1,499 shares during the period. Tsfg LLC’s holdings in Pfizer were worth $136,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Mather Group LLC. increased its holdings in Pfizer by 35.0% during the 3rd quarter. Mather Group LLC. now owns 34,169 shares of the biopharmaceutical company’s stock worth $1,133,000 after purchasing an additional 8,857 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Pfizer by 97.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 183,802 shares of the biopharmaceutical company’s stock valued at $6,097,000 after acquiring an additional 90,896 shares during the period. Cape Cod Five Cents Savings Bank increased its holdings in shares of Pfizer by 103.6% in the 3rd quarter. Cape Cod Five Cents Savings Bank now owns 57,884 shares of the biopharmaceutical company’s stock valued at $1,920,000 after acquiring an additional 29,459 shares during the period. Teza Capital Management LLC purchased a new position in shares of Pfizer in the 3rd quarter valued at $347,000. Finally, Ironwood Investment Counsel LLC increased its holdings in shares of Pfizer by 4.9% in the 3rd quarter. Ironwood Investment Counsel LLC now owns 40,639 shares of the biopharmaceutical company’s stock valued at $1,348,000 after acquiring an additional 1,913 shares during the period. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on PFE shares. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday. Morgan Stanley lifted their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Finally, BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $35.86.

Pfizer Stock Performance

Shares of PFE stock opened at $27.99 on Friday. The stock has a market cap of $158.61 billion, a PE ratio of -466.42, a price-to-earnings-growth ratio of 1.09 and a beta of 0.70. The business has a 50-day simple moving average of $27.90 and a 200-day simple moving average of $27.69. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.80.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.23 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.